Working Together on Challenges We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines. We work closely with organisations that have unique technologies to address our patients’ unmet needs around the globe. Through the CSL Research Acceleration Initiative (RAI), we work with a network of over 330 research organisations across 26 countries. Through long‑term collaborations with academic scientists, the RAI promotes innovation by providing early funding and access to our R&D experts to help advance new technologies and assets towards real-world treatments. To date, the RAI has funded 38 programs. Of these, 23 have been completed – four transitioned to CSL’s research division and 19 were terminated, representing a 17% probability of success. We also form strategic partnerships with incubators, accelerators and venture funders to build the broader ecosystem. One of the biggest barriers to translating and commercialising medical research is the lack of capital and access to expertise. In FY2025, we committed $25 million in Brandon Capital’s new fund, Brandon BioCatalyst Fund 6 (BB6). With over $1 billion under management and a strong track record of successful biotech ventures, by investing in Brandon Capital’s BB6 fund we have access to a curated network of more than 50 medical research institutes, universities and hospitals across Australia and New Zealand, enhancing opportunities for cutting‑edge innovation. In October 2024, CSL became the cornerstone industry investor in Biofund IV, a dedicated healthcare fund with a European focus. Europe is a rich source of early-stage external innovation for CSL and is home to 43 of the world’s top 100 life science universities. Managed by Kurma Partners, Biofund IV has already made its first three investments and aims to support 16 to 20 companies. Like its predecessors, Biofund IV focuses on companies developing innovative therapeutics, following a balanced, risk-managed strategy that includes both company creation and investments in established venture-stage companies. The Jumar Bioincubator: Supporting Biotech Entrepreneurs Our Global Headquarters and Centre for Research & Development in Melbourne, Australia, is home to Jumar Bioincubator, a world‑class hub supporting 34 biotech companies – 28 of which are startups. Delivered in partnership with WEHI, the University of Melbourne, as well as initial investor Breakthrough Victoria and operator Cicada Innovations, Jumar delivers a wide range of services, including educational programs on commercialisation, facilitated access to investors, industry mentoring and access to specialist service providers. Jumar offers comprehensive support to biotech start-ups, supporting them to translate groundbreaking biomedical discoveries into tangible commercial outcomes. The name ‘jumar’ refers to a mountaineering technique by which climbers receive the support necessary to efficiently scale and speedily ascend challenging mountains. By providing a first home for young aspiring biotech ventures, the Jumar Bioincubator similarly aims to help biotech entrepreneurs to ascend and scale the heights of their industry. >330 research organisations in our network across 26 countries, accelerating the development and commercialisation of promising discoveries through the CSL Research Acceleration Initiative 38 programs funded under the CSL Research Acceleration Initiative Dr Christos Papadimitriou, CEO & Managing Director of Tessara Therapeutics. Residents of the Jumar Incubator, Tessara Therapeutics is developing cutting-edge ‘minibrain’ technology to accelerate research into neurodegenerative diseases. Image © City of Melbourne 2024, photography: Louis Trerise Photography PTY LTD. 20 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
RkJQdWJsaXNoZXIy MjE2NDg3